论文部分内容阅读
目的:构建体外、体内模型,探讨罗默碱抗前列腺癌活性。方法:检测罗默碱对多种前列腺癌细胞(DU145、LNCa P、PC-3和22RV1)增殖、凋亡和迁移的影响,筛选敏感肿瘤细胞系,构建裸鼠荷瘤模型,进一步验证罗默碱的体内抗肿瘤药效。结果:罗默碱对DU145、LNCaP、PC-3和22RV1细胞增殖和迁移均具有不同程度的抑制作用,对其细胞凋亡亦具有不同程度的诱导作用,其中以LNCaP细胞最为敏感。裸鼠荷LNCaP肿瘤模型中,罗默碱单独干预组肿瘤重量[(1.99±0.95)g]显著低于对照组[(2.95±1.04)g],P<0.01;而高剂量罗默碱(30 mg/kg)和紫杉醇联合干预组肿瘤重量[(0.90±0.16)g]均显著小于其他3组(P<0.05或P<0.01)。罗默碱单独干预组裸鼠的心脏脏器系数(0.58±0.06)、肝脏脏器系数(6.20±0.42)和肾脏脏器系数(1.49±0.33)均不同程度低于紫杉醇单独干预组(0.66±0.04、6.99±0.72和1.95±0.34,P均<0.05),脾脏脏器系数(0.54±0.11)和胸腺脏器系数(0.06±0.01)显著高于紫杉醇单独干预组(0.41±0.09、0.05±0.01,P均<0.05)。病理结果显示罗默碱干预组及联合给药组中肿瘤恶变程度和肿瘤转移程度低于对照组,罗默碱干预组及联合给药组中小鼠内脏损伤明显小于紫杉醇组水平。结论:罗默碱发挥一定的抗前列腺肿瘤功效,同时联合化疗药给药时可以降低其毒性。
OBJECTIVE: To construct in vitro and in vivo models to investigate the activity of Rotemerine against prostate cancer. Methods: The effects of ROR on the proliferation, apoptosis and migration of various prostate cancer cells (DU145, LNCa P, PC-3 and 22RV1) were detected. The sensitive tumor cell lines were screened and the tumor-bearing model was established in nude mice. Alkali anti-tumor efficacy in vivo. RESULTS: Rotemerine inhibited the proliferation and migration of DU145, LNCaP, PC-3 and 22RV1 cells to varying degrees and induced apoptosis to varying degrees. LNCaP cells were most sensitive to them. In the nude mice bearing LNCaP tumor model, the tumor weight [(1.99 ± 0.95) g] was significantly lower than that of the control group [(2.95 ± 1.04) g], P <0.01 (0.90 ± 0.16) g] were significantly lower than those in the other three groups (P <0.05 or P <0.01). RTE alone (0.58 ± 0.06), liver organ coefficient (6.20 ± 0.42) and renal organ coefficient (1.49 ± 0.33) were significantly lower in nude mice than those treated with paclitaxel alone (0.66 ± (P <0.05). The spleen organ coefficient (0.54 ± 0.11) and thymus organ coefficient (0.06 ± 0.01) were significantly higher than those of paclitaxel alone group (0.41 ± 0.09,0.05 ± 0.01, P < , P <0.05). The pathological results showed that the degree of tumor malignancy and the degree of tumor metastasis in the Romine alkali treatment group and the combination treatment group were lower than those in the control group. The visceral injury in the Romerine alkali treatment group and the combination treatment group was significantly smaller than that in the paclitaxel group. Conclusion: Romerine exerts some anti-prostate tumor efficacy, and its toxicity can be reduced when combined with chemotherapy drugs.